Citadel Advisors’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-342,195
| Closed | -$544K | – | 15852 |
|
|
2024
Q1 | $544K | Buy |
342,195
+270,021
| +374% | +$401K | ﹤0.01% | 8194 |
|
|
2023
Q4 | $62K | Sell |
72,174
-91,972
| -56% | -$80.8K | ﹤0.01% | 11554 |
|
|
2023
Q3 | $176K | Sell |
164,146
-182,344
| -53% | -$377K | ﹤0.01% | 10126 |
|
|
2023
Q2 | $897K | Buy |
346,490
+269,101
| +348% | +$960K | ﹤0.01% | 6682 |
|
|
2023
Q1 | $316K | Buy |
77,389
+50,997
| +193% | +$236K | ﹤0.01% | 9280 |
|
|
2022
Q4 | $132K | Sell |
26,392
-267,743
| -91% | -$1.68M | ﹤0.01% | 10800 |
|
|
2022
Q3 | $3.85M | Buy |
294,135
+66,414
| +29% | +$1.01M | ﹤0.01% | 4319 |
|
|
2022
Q2 | $2.92M | Buy |
227,721
+69,928
| +44% | +$968K | ﹤0.01% | 4800 |
|
|
2022
Q1 | $2.41M | Sell |
157,793
-536,354
| -77% | -$8.37M | ﹤0.01% | 5694 |
|
|
2021
Q4 | $12.3M | Sell |
694,147
-64,508
| -9% | -$1.24M | ﹤0.01% | 2714 |
|
|
2021
Q3 | $15.9M | Buy |
758,655
+50,576
| +7% | +$1.11M | ﹤0.01% | 2338 |
|
|
2021
Q2 | $14M | Buy |
708,079
+327,650
| +86% | +$7.67M | ﹤0.01% | 2574 |
|
|
2021
Q1 | $11.1M | Buy |
380,429
+214,036
| +129% | +$5.99M | ﹤0.01% | 2833 |
|
|
2020
Q4 | $5.04M | Buy |
166,393
+125,036
| +302% | +$2.74M | ﹤0.01% | 3674 |
|
|
2020
Q3 | $658K | Buy |
41,357
+13,404
| +48% | +$245K | ﹤0.01% | 6803 |
|
|
2020
Q2 | $551K | Sell |
27,953
-176,968
| -86% | -$3.38M | ﹤0.01% | 6909 |
|
|
2020
Q1 | $2.53M | Buy |
204,921
+167,388
| +446% | +$2.73M | ﹤0.01% | 3766 |
|
|
2019
Q4 | $694K | Buy |
37,533
+14,118
| +60% | +$206K | ﹤0.01% | 6265 |
|
|
2019
Q3 | $325K | Buy |
23,415
+3,700
| +19% | +$55.5K | ﹤0.01% | 7446 |
|
|
2019
Q2 | $289K | Buy |
+19,715
| New | +$289K | ﹤0.01% | 7640 |
|
Citadel Advisors's NGM Position: Q2 2024 in Review
Citadel Advisors sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 342,195 shares — an estimated $544K sold.
Citadel Advisors first reported a position in NGM in Q2 2019 and held it in 20 quarters. The position peaked at $15.9M in Q3 2021. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- Citadel Advisors reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Citadel Advisors sold 342,195 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $544K.
- Citadel Advisors first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 20 quarters.
- Citadel Advisors's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $15.9M in Q3 2021.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.